Eloxx Pharmaceuticals Announces FDA Clearance of IND for Exaluren in Nonsense-Mutation ADPKD

Article summary

Eloxx Pharmaceuticals has received FDA clearance for its Investigational New Drug application to initiate a global Phase 2 clinical trial of exaluren for nonsense-mutation ADPKD.